Biopharma Turnaround and Crisis Management
Biopharma crises are more common than they appear from the outside - and more recoverable than they feel from the inside. A 2025 analysis by the Journal of Commercial Biotechnology found that approximately 35% of clinical-stage biopharma companies experience a significant operational, financial, or strategic crisis within their first seven years. Of those, companies that engaged experienced external turnaround support within the first 90 days recovered 60% faster than those that relied solely on internal management. The difference between a company that survives a crisis and one that does not is rarely the severity of the crisis - it is the speed and quality of the response.
The most common triggers of biopharma crises in 2026 include clinical trial failures - which affected 89% of oncology programs entering Phase III in 2024, according to the Biotechnology Innovation Organization - capital market dislocations, FDA complete response letters, key executive departures, supply chain failures, and post-acquisition integration breakdowns. Each of these scenarios requires a different response - but all of them require the same foundation: experienced operator judgment, decisive action, and the organizational credibility to lead a board, a management team, and an investor base through uncertainty.
Drawing on 18 years of direct CEO experience managing organizational stabilization, balance sheet restructuring, strategic reorientation, and stakeholder management under real-time pressure. We have been in the room when the hardest decisions had to be made and we bring that experience, and the equanimity that comes with it, to every turnaround engagement.
What We Do
Situation Assessment
The first step in any turnaround is an honest, rapid assessment of the situation — the financial position, the operational reality, the competitive landscape, and the strategic options available. We do not soften the diagnosis. We give leadership teams and boards the clear picture they need to make the right decisions.
Balance Sheet and Capital Strategy
Many biopharma crises have a capital dimension — a runway that is shorter than it appears, a capital structure that is not supportable, or a financing need that the current investor base cannot or will not meet. We help companies restructure their balance sheet, identify new capital sources, and build the financial narrative needed to attract capital in difficult circumstances.
Strategic Reorientation
Sometimes a turnaround requires a fundamental change in strategic direction — a new target indication, a pivot in business model, a portfolio rationalization, or a shift in commercial strategy. We help leadership teams make those decisions with clarity and conviction
Leadership and Organizational Stabilization
Crisis situations destabilize organizations. Key talent leaves. Teams lose confidence. Execution slows at exactly the moment speed is most critical. We help companies stabilize their leadership and organizational dynamics — retaining the people who matter most and rebuilding the execution capability needed to move forward.
Stakeholder Management
Board management, investor communication, regulatory engagement, and partner relations all require careful, coordinated management in a crisis situation. We help leadership teams build and execute stakeholder communication strategies that maintain confidence and preserve optionality.
Built for the Operator's Seat
Who This Is For?
Boards, CEOs, and executive teams at biopharma companies navigating a significant operational, financial, regulatory, or strategic change, or companies that are performing adequately but recognize that decisive intervention is needed to reach their potential.
Why Katogen?
We have been in the room when the hard decisions had to be made. We have led organizations through clinical failures, capital crises, leadership transitions, and strategic pivots. We bring that experience — and the equanimity that comes with it — to every turnaround engagement.
WORK WITH KATOGEN
If you are navigating a strategic inflection point — a capital raise, an acquisition, a turnaround, a regulatory challenge, or simply a moment where you need an experienced operator in your corner — we would welcome the conversation. Engagements are selective. The first step is a direct conversation to understand your situation and determine where Katogen can add the most value.